buflomedil
Buflomedil, sold under the brand name Loftyl, is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. It is currently not approved by the Food and Drug Administration (FDA) for use in the United States.
Research
334 papers- Buflomedil for acute ischaemic stroke.The Cochrane database of systematic reviews · 2015
- Buflomedil for intermittent claudication.The Cochrane database of systematic reviews · 2013
- Buflomedil for intermittent claudication.The Cochrane database of systematic reviews · 2008
- Buflomedil for intermittent claudication.The Cochrane database of systematic reviews · 2007
- Buflomedil for intermittent claudication.The Cochrane database of systematic reviews · 2001
via PubMed
Article
3 sectionsContents
- Toxicity
- Synthesis
- References
Buflomedil, sold under the brand name Loftyl, is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. It is currently not approved by the Food and Drug Administration (FDA) for use in the United States.
==Toxicity== This drug has been suspended from marketing in the European Union, because of concerns about severe neurological and cardiac toxicity. In its press release dated 17 November 2011 EMA suggested that doctors "should stop using buflomedil and consider alternative treatment options". The European Commission advised all member states to revoke marketing authorisation.